Clinigen Group PLC (CLIN) Receives “Add” Rating from Peel Hunt
Clinigen Group PLC (LON:CLIN)‘s stock had its “add” rating reiterated by analysts at Peel Hunt in a research note issued on Wednesday. They currently have a GBX 1,200 ($15.50) price target on the stock. Peel Hunt’s target price suggests a potential upside of 8.01% from the company’s current price.
CLIN has been the subject of several other reports. Numis Securities Ltd lowered shares of Clinigen Group PLC to an “add” rating and set a GBX 1,100 ($14.21) price objective for the company. in a research report on Tuesday, July 18th. Stifel Nicolaus reissued a “buy” rating and set a GBX 970 ($12.53) price target on shares of Clinigen Group PLC in a research report on Monday, May 22nd.
Shares of Clinigen Group PLC (LON:CLIN) opened at 1062.00 on Wednesday. The company’s market capitalization is GBX 1.22 billion. Clinigen Group PLC has a 12 month low of GBX 635.00 and a 12 month high of GBX 1,149.00. The company’s 50-day moving average is GBX 1,057.78 and its 200 day moving average is GBX 904.56.
In other Clinigen Group PLC news, insider John Bacon sold 200,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 28th. The shares were sold at an average price of GBX 843 ($10.89), for a total transaction of £1,686,000 ($2,177,450.60). Also, former CEO Peter George sold 500,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of GBX 875 ($11.30), for a total transaction of £4,375,000 ($5,650,264.76).
About Clinigen Group PLC
Receive News & Ratings for Clinigen Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.